How to Screen Treatment-Resistant Bipolar Depression for Insulin Resistance
How should clinicians identify patients with treatment-resistant bipolar depression who may be candidates for insulin resistance-targeted treatment?
Patients with treatment-resistant bipolar depression often remain significantly symptomatic despite recommended mood-stabilizing treatment. This trial identified insulin resistance as a clinically relevant subtype, using a specific metabolic screening approach to find patients who might benefit from insulin-sensitizing treatment.
-
Confirm bipolar disorder and persistent depressive symptoms
Apply this workflow to adults with DSM-5 bipolar I or bipolar II disorder who have ongoing depressive symptoms. In the trial, patients had unremitting depression with a Montgomery-Asberg Depression Rating Scale score of 15 or higher for at least 4 weeks.
-
Verify that current treatment meets a treatment-resistant standard
Establish that depressive symptoms persist despite optimal mood-stabilizing treatment. In the study, optimal treatment meant mood-stabilizing monotherapy or medication combinations at stable doses consistent with 2013 Canadian Network for Mood and Anxiety Treatments guidelines for at least 4 weeks, and the article frames treatment-resistant bipolar depression as failure to reach sustained remission after two 8-week trials of recommended medications at therapeutic doses.
-
Measure fasting glucose and fasting serum insulin
Obtain concurrent fasting plasma glucose and fasting serum insulin concentrations. These values are needed to calculate the Homeostatic Model Assessment-Insulin Resistance value used in the study to identify insulin resistance.
-
Calculate HOMA-IR and apply the study cutoff
Use the HOMA-IR equation to determine whether insulin resistance is present. The trial defined insulin resistance as HOMA-IR of 1.8 or higher and excluded patients who did not meet this threshold.
-
Exclude type 2 diabetes mellitus and major safety contraindications
Do not use this study pathway for patients who already have type 2 diabetes mellitus, because those patients were screened out. Also exclude patients with rapid cycling, manic symptoms with Young Mania Rating Scale score of 15 or higher, current suicidal ideation rated 5 on the Columbia-Suicide Severity Rating Scale, metformin use within 2 weeks, metformin allergy, liver function tests 3 times the reference value or higher, estimated glomerular filtration rate 30 mL/min/1.73m2 or lower, pregnancy, or breastfeeding.
-
Document baseline psychiatric and medical status before treatment
Before initiating an insulin resistance-targeted intervention, obtain baseline depressive symptoms, manic symptoms, suicidal ideation, functioning, and anxiety ratings. The study also performed physical examination, medical and psychiatric history review, renal and liver function testing, body weight, body mass index, blood pressure, pregnancy testing in reproductive-aged women, urine drug screening, electrocardiography, complete blood cell counts, thyroid testing, lipids, and blood mood stabilizer levels.
Clinical Considerations
- This screening approach was studied only in adults with bipolar I or II disorder who had treatment-resistant bipolar depression and insulin resistance, not in broader bipolar populations.
- Patients with type 2 diabetes mellitus were excluded, so the article does not support applying this protocol to bipolar depression with established diabetes.
- The study used a HOMA-IR cutoff of 1.8, selected because metabolic syndrome becomes clinically significant at this value.
- The trial’s small sample size limits certainty about which insulin-resistant patients are most likely to benefit after screening.
Bottom Line
In treatment-resistant bipolar depression, checking fasting glucose and fasting insulin to calculate HOMA-IR can identify an insulin-resistant subgroup with a potentially treatable metabolic driver.
